Skip to main content
SpringerLink
Log in

Morbus Hodgkin

  • Chapter
Book cover Therapiekonzepte Onkologie

  • 66 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Correa P, O’Connor GT (1971) Epidemiologic patterns of Hodgkin’s disease. Int J Cancer 8:192–201

    Article  PubMed  CAS  Google Scholar 

  2. Glaser SL (1990) Hodgkin’s disease in black populations. A review of the epidemiologic literature. Sem Oncol 6:643–659

    Google Scholar 

  3. Carde P, Hagenbeek A, Hayat M et al. (1993) Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin’s disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258–2272

    PubMed  CAS  Google Scholar 

  4. Kaplan MS (1980) Hodgkin’s disease. Cambridge, Harvard University Press

    Google Scholar 

  5. Canellos GP, Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkins’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484

    Article  PubMed  CAS  Google Scholar 

  6. Viviani S, Bonadonna G, Santoro A et al. (1996) Alternating versus hybrid MOPP and ABVD combinations in advanded Hodgkin’s disease: Ten-year results. J Clin Oncol 14:1421–1430

    PubMed  CAS  Google Scholar 

  7. Connors JM, Klimo P, Adams G et al. (1997) Treatment of advanced Hodgkin’s disease with chemotherapy — comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:1638–1645

    PubMed  CAS  Google Scholar 

  8. Diehl V, Tesch H, Lathan B et al. (1997) BEACOPP, a new intensified regimen, is at least equally effective compared with COPP/ABVD in patients with advanced stage Hodgkin’s lymphoma. Proc A Soc Clin Oncol 16:7a (Abstr. 5)

    Google Scholar 

  9. Diehl V, Pfreundschuh M, Löffler M et al. (1990) Cooperative trials of Hodgkin’s lymphoma in the Federal Republic of Germany. J Cancer Res Clin Oncol 116:106–108

    Article  PubMed  CAS  Google Scholar 

  10. Lathan B, Pfreundschuh M, Löffler M et al. (1993) Therapiestrategien des Morbus Hodgkin. Internist 34:146–154

    PubMed  CAS  Google Scholar 

  11. Longo DL, Duffey PL, Young RC et al. (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210–228

    PubMed  CAS  Google Scholar 

  12. Pfreundschuh MG, Rueffer U, Lathan B et al. (1984) Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin’s Disease Study Group. J Clin Oncol 12:580–586

    Google Scholar 

  13. DeVita VT (1979) Comination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:881–895

    Article  Google Scholar 

  14. Morgenfeld M (1972) Treatment of malignant lymphoma with cyclophosphamide, vincristine, procarbazine and prednisone combination. XIV Internat Congr Hematolog Sao Paulo (abstr. 578)

    Google Scholar 

  15. Bonadonna G (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastin and imidazole carboxamide versus MOPP. Cancer 36:252–259

    Article  PubMed  CAS  Google Scholar 

  16. Diehl V, Sieber M, Rüffer U et al. (1997) BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin’s disease. Ann Oncol 8:143–148

    Article  PubMed  CAS  Google Scholar 

  17. Pfreundschuh MG, Schoppe WD, Fuchs R et al. (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin’s lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and Doxorubicin, Bleomycin, vinblastine, and dacarbazine (ABVD): A trial of the German Hodgkin Study Group. Cancer Treat Rep 71:1203–1207

    PubMed  CAS  Google Scholar 

  18. Santoro A, Viviani SS, Valagussa P et al. (1986) CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin’s disease. Semin Oncol 13:23–26

    PubMed  CAS  Google Scholar 

  19. Rosenberg SA, Kaplan HS (1985) The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin’s disease. Oncol Biol Phys 11:5–22

    Article  CAS  Google Scholar 

  20. Carde P, Burgers J, Henry-Amar M et al. (1988) Clinical stages I and II Hodgkin’s disease: A specifically tailored therapy according to prognostic factors. J Clin Oncol 6:239–252

    PubMed  CAS  Google Scholar 

  21. Dühmke E, Diehl V, Loeffler M et al. (1996) Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiation Oncology Biol Phys 36:305–310

    Article  Google Scholar 

  22. Horning SJ, Hoppe RT, Hancock SL et al. (1988) Vinblastine, bleomycine, and methotrexate: An effecitve adjuvant in favorable Hodgkin’s disease. J Clin Oncol 6:1822–1831

    PubMed  CAS  Google Scholar 

  23. Longo DL, Glatstein E, Duffey PL et al. (1991) Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease: Seven-year results of a prospective randomized trial. J Clin Oncol 9:906–917

    PubMed  CAS  Google Scholar 

  24. Biti GP, Cimino G, Cartoni C et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I–IIA Hodgkin’s disease: Eight-year update of an italian prospective randomized study. J Clin Oncol 10:378–382

    PubMed  CAS  Google Scholar 

  25. Carde P, Noordijk EM, Hagenbeek A et al. (1997) Superiority of EBVP chemotherapy in combination with involvedl field irradiation (EBVP/IF) over subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I–II Hodgkin’s disease: the EORTC — GPMC H7F randomized trial. Proc A Soc Clin Oncol 16:13a (Abstr. 44)

    Google Scholar 

  26. Tesch H, Brosteanu O, Hasenclever D et al. (1996) Comparison of COPP/ABVD and COPP/ABV/IMEP in the treatment of Hodgkin’s disease. Results of HD5 and HD6 studies of the German Hodgkin Study Group. Ann Oncol 7(Suppl. 3):50 (Abstr. 170)

    Google Scholar 

  27. Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. Ann Intern Med 104:739–746

    Article  PubMed  CAS  Google Scholar 

  28. Longo DL, Duffey PL, DeVita VT et al. (1991) Treatment of advanced-stage Hodgkin’s disease: Alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol 9:1409–1420

    PubMed  CAS  Google Scholar 

  29. Duggan D, Petroni G, Johnson J et al. (1997) MOPP/ABV versus ABVD for advanced Hodgkin’s disease — preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc A Soc Clin Oncol 16:12 a (Abstr. 43)

    Google Scholar 

  30. Tseng A, Jacobs C, Coleman CN et al. (1987) Third-line chemotherapy for resistant Hodgkin’s disease with lomustine, etoposide, and methotrexate. Cancer Treat Rep 71:475–478

    PubMed  Google Scholar 

  31. Hagemeister FB, Tannir N, McLauglin P et al. (1987) MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin’s disease. J Clin Oncol 5:556–561

    PubMed  CAS  Google Scholar 

  32. Longo DL (1990) The use of chemotherapy in the treatment of Hodgkin’s disease. Semin Oncol 17:716–735

    PubMed  CAS  Google Scholar 

  33. Gribben GJ, Linch DC, Singer CRJ et al. (1989) Successful treatment of refractory Hodgkin’s disease by high-dose chemotherapy and autologous bone marrow transplantation. Blood 73:340–344

    PubMed  CAS  Google Scholar 

  34. Jagannath S, Armitage JO, Dicke KA et al. (1989) Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 7:179–185

    PubMed  CAS  Google Scholar 

  35. Philips GL, Wolff SN, Herzig RH et al. (1989) Treatment of progressive Hodgkin’s disease with intensive chemoradiotherpy and autologous bone marrow transplantation. Blood 73:2086–2092

    Google Scholar 

  36. Wheeler C, Antin JH, Churchill WH et al. (1990) Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin’s disease and non-Hodgkin’s lymphoma: A dose-finding study. J Clin Oncol 8:648–656

    PubMed  CAS  Google Scholar 

  37. Reece DE, Barnett MJ, Connors JM et al. (1991) Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 9:1871–1879

    PubMed  CAS  Google Scholar 

  38. Schmitz N, Glass B, Dreger P et al. (1993) High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin’s disease. Ann Hematol 66:251–256

    Article  PubMed  CAS  Google Scholar 

  39. Reece DE, Connors JM, Spinelli JJ et al. (1994) Intensive therapy with Cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood 83:1193–1199.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Sieber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Lathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Diehl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Sieber, M., Lathan, B., Diehl, V. (1998). Morbus Hodgkin. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation